Why the study?
Approximately 20% of AMI patients with multivessel disease experience adverse outcomes after complete revascularization, prompting investigation into the metabolic mechanisms of ischemia-reperfusion injury responsible for abnormal hemodynamic stresses.
Are elevated levels of long-chain acylcarnitines (LCACs) associated with increased major adverse cardiovascular events (MACEs) in patients with acute myocardial infarction and multivessel disease undergoing complete revascularization?
Are elevated levels of long-chain acylcarnitines (LCACs) associated with increased major adverse cardiovascular events (MACEs) in patients with acute myocardial infarction and multivessel disease undergoing complete revascularization?
Reperfusion of non-culprit lesions in AMI with multivessel disease drives endothelial CPT1A activation and long-chain acylcarnitine accumulation, leading to cardiomyocyte mitochondrial dysfunction and poor prognosis, revealing a novel mechanism and therapeutic target.
LCAC 16:1 elevation signals post-revascularization risk; porcine CPT1A inhibition extends mechanistic insight but leaves clinical translation open.
Approximately 20% of acute myocardial infarction (AMI) patients with multivessel disease experience adverse outcomes after complete revascularization. We aim to investigate the underlying metabolic mechanism of ischemia-reperfusion injury responsible for abnormal hemodynamic stresses in high-risk patients undergoing complete revascularization. Elevated preoperative serum levels of long-chain acylcarnitine (LCAC) 16:1 are associated with an increased risk of poor prognosis following complete revascularization. Multi-omics analyses reveal that reperfusion injury activates fatty acid degradation, and carnitine palmitoyltransferase 1A (CPT1A) is identified as a key regulator of LCACs in the interaction network in porcine models. In the early stages of reperfusion injury in non-culprit lesions, the release and prolonged elevation of circulating LCACs primarily depend on the activation of endothelial CPT1A through hemodynamic injury, which can be reduced using an inhibitor (etomoxir). Excess LCACs enter cardiomyocytes via the organic cation transporter 2, leading to imbalanced mitochondrial quality control and causing cardiomyocyte death.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: